After the applause: New efficacy expectations in urothelial cancer after Padcev-Keytruda data reveal
Urothelial cancer oncologist Matthew Galsky has trouble remembering the last time there was a standing ovation for clinical trial data at a medical conference. But he wasn’t surprised that confirmatory data from a Phase III trial studying Seagen and Astellas’ Padcev plus Merck’s Keytruda in first-line bladder cancer was met with one just over a week ago at ESMO.
“Since the development of platinum-based chemotherapy around 30-plus years ago, there have been no improvements in survival in patients with metastatic bladder cancer or urothelial cancer,” said Galsky, a professor at the Icahn School of Medicine at Mount Sinai.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.